Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445588 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
A Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 9
- Study locations
NCT00445588 is a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants, above the 40-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (40% higher). The trial reports 9 study locations across 9 states.
The verdict
NCT00445588, a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving erlotinib together with sorafenib may kill more tumor cells.
Conditions Studied
Interventions
- OTHER pharmacological study
- DRUG erlotinib hydrochloride
- DRUG sorafenib tosylate
Study Locations (9)
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Hospital - Detroit
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00445588
The ClinicalTrials.gov registry entry for NCT00445588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 40-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (40% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which pharmacological study is the first listed.
NCT00445588 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00445588 about?
NCT00445588 is a clinical study titled "Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme". This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood ...
What is the current status of trial NCT00445588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2007-01. Estimated completion is 2009-08.
What conditions does trial NCT00445588 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor.
What interventions are being tested in trial NCT00445588?
The interventions under investigation include: pharmacological study (OTHER), erlotinib hydrochloride (DRUG), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00445588?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00445588 being conducted?
This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
COMPLETED · Phase 2
-
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
COMPLETED · Phase 2
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.